Singapore Exchange (“SGX”) is pleased that Lonza Group Ltd (“Lonza”), one of the world’s leading suppliers to the pharmaceutical, healthcare and life science industries, is listed today on its Mainboard by way of a secondary listing. Lonza is the first primary-listed company on the SIX Swiss Exchange to be dual-listed on the SGX Mainboard, trading under the ticker symbol of “O6Z”.
Lonza is headquartered in Basel, Switzerland. It is one of the largest global contract manufacturers for the pharmaceutical and biopharmaceutical industry. In the life science ingredients sector, it is a wellestablished market participant with over 50% market share in a growing number of niche segments. It has 45 production and R&D facilities throughout Asia, Europe and the United States. Its Asian presence is underscored by its six manufacturing and R&D facilities in China, Singapore, India and Japan. Its choice of SGX Asian Gateway is a further commitment to its expansion plans in Asia.
Commenting on the listing, Mr Stefan Borgas, Chief Executive Officer of Lonza Group Ltd, said, “Lonza’s secondary listing in Singapore marks a new and exciting chapter for the Company. Asia is an increasingly important market for Lonza, and our over-proportional market growth is the key driver for investments in Asia.
As we expand in the region, Asian based investors have recognized Lonza’s growth potential in the life science markets. Our Singapore listing will enable us to broaden our investor base in Asia as well as enhance our corporate profile in the region with customers and employees. This will enable the Group to further tap into the market growth in Asia.”
Mr Magnus Böcker, Chief Executive Officer, Singapore Exchange shared, “I am pleased to welcome the Lonza Group to SGX. The listing of Lonza is significant to the Singapore’s Bioscience and Healthcare industry. It is also exciting for SGX as we continue to extend our position as the preferred venue for companies with a focus on the Asian region. We look forward to more European and US businesses coming to Singapore and leveraging on SGX as their gateway to Asian liquidity”.
With a market capitalisation of about S$ 4.2 billion, Lonza brings the total number of listed companies on SGX to 774.
